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INTRODUCTION
Transfusion-associated primary cytomegalovirus (CMV)
disease is known to cause significant morbidity and mortal-
ity among premature infants born with birth weights less
than 1.5 kg (very low birth weight infants, VLBWI) (1). CMV
transmission via blood transfusion can best be prevented by
using only blood products from CMV seronegative donors.
However, the prevalence of CMV seropositivity among blood
donors limits the availability of seronegative blood products
in hyperendemic area such as Korea, where donor blood is not
routinely screened for CMV antibodies. To date, few studies
have examined the incidence of CMV infection acquisition
through transfusion in VLBWI in endemic areas. Without
knowledge of this incidence, there is little information avail-
able for determining best transfusion practices for reduction
of transfusion-acquired CMV infection in endemic areas. As
a result, standardization of transfusion policies in Korean hos-
pitals is lacking. We sought to investigate the incidence of
acquired CMV infection in a hyperendemic area when VLBWI
were given CMV IgG-positive blood. We compared the inci-
dence and characterization of VLBWI who acquired CMV
infection when using filtered-irradiated versus nonfiltered-
nonirradiated blood, and examined the time required for
VLBWI to clear passively-derived anti-CMV IgG.
MATERIALS AND METHODS
Subjects
We compared the incidence of acquired CMV in two neona-
tal intensive care units (NICUs) with different transfusion
practices. We enrolled all VLBWI admitted to the NICU of
hospital A between 1 February 2000 and 30 June 2001 and
all VLBWI admitted to NICU of hospital B during the same
time period, who required either packed RBC (PRBC) or
platelet transfusions.
In hospital A, the routine procedure was to transfuse blood
products that had been filtered through RCXLTM (Pall Biomed-
ical, Inc., East Hills, NY, U.S.A.) for PRBC and PXLTM8
(Pall Biomedical Inc.) for platelets. In hospital B, the routine
policy was to use nonfiltered-nonirradiated blood products.
VLBWI from either hospital were excluded from the analy-
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Transfusion-related Cytomegalovirus Infection Among Very Low Birth
Weight Infants in an Endemic Area
This study investigated the incidence of acquired cytomegalovirus (CMV) infection
in very low birth weight infants (VLBWI) given CMV seropositive blood, and sought
to determine whether filtering and irradiation of blood products could help prevent
CMV infection and the time required to clear passively-derived anti-CMV IgG among
80 VLBWI transfused with filtered-irradiated blood, 20 VLBWI transfused with non-
filtered-nonirradiated blood and 26 nontransfused VLBWI. CMV IgG and IgM values
were obtained from all blood products prior to transfusions, and from VLBWI at birth
until the infants became seronegative. Urine was obtained for CMV culture at birth
and every 3-4 weeks until 12 weeks after the final transfusion. The incidence of
CMV IgG seropositivity among the 126 infants at birth and the blood products given
were 96% and 95%, respectively. The incidence of acquired CMV infection was
4/100 (4%) in the transfused group: 2/80 (2.5%) and 2/20 (10%) in the filtered-irra-
diated and nonfiltered-nonirradiated transfusion groups, respectively. Approximately
9-10 months elapsed to clear passively acquired CMV IgG. The irradiation and fil-
tering of the blood products did not seem to decrease the transfusion-related CMV
infection rate in Korea among VLBWI, however, further validation is recommended
in a larger cohort of infants.
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sis if: 1) they had congenital CMV infection as evidenced by
positive urine CMV culture within 2 weeks of life, 2) out-
patient department (OPD) follow-up was not possible, as
study subjects were followed until CMV seronegativity was
documented, 3) they expired during study period, or 4) par-
ents did not consent. 
The guidelines for PRBC (2) and platelet (3) transfusions
were followed strictly at both hospitals. In each instance, the
volume of blood given per transfusion was 10-15 mL/kg.
Some VLBWI from both hospitals were fed their own mother’s
expressed breast milk, which had been frozen at -20℃ for
4-10 days and thawed just prior to each feeding. None were
fed fresh maternal or fresh banked breast milk and breast
milk given in both hospitals were not evaluated by CMV
culture/PCR for infectivity. Parental consents were obtained
prior to enrolling subjects. This study was approved by the
institutional review board of the Asan Medical Center and
Samsung Cheil Hospital.
Tests on transfused blood and VLBWI
Aliquots of all transfused PRBC anticoagulated with CPD
solutions and platelet concentrates provided to hospitals A
and B by the Korean Red Cross were tested for total CMV
IgG and IgM by enzyme linked fluorescent assay (VIDAS
CMV IgG, IgM, bioMerieux, Marcy-l’Etoile/France). All
blood donors were screened for hepatitis B, C, HIV, Trepone-
ma pallidum, and liver function tests, to exclude other infec-
tion. In hospital A, PRBC units were divided into three bags
by an aseptic technique (last bag to be used within 14 days
of preparation), limiting patient-donor exposures. In these
cases, one bag per donor was tested for CMV IgG and IgM. 
All RBC products and platelet concentrates, usually 8-11
days and 4-5 days old after donation, respectively, were irra-
diated at 25 Gy for 179 sec (CIS biointernational, Filiale de
Compagnie ORIS Industrie S.A., France) prior to transfusion
to prevent postransfusion graft-versus-host disease. The inst-
rument was dosimetrically checked (International Specialty
Products, RAD-SURETM, Wayne, NJ, U.S.A.). At hospital
B, transfused blood products of 3-5 days and 2-3 days old
PRBC and platelets, respectively, were not filtered nor irra-
diated prior to transfusion. All subjects were tested for CMV
IgG and IgM (VIDAS CMV IgG, IgM, bioMerieux, Marcy-
l’Etoile/France) at birth and every 3-4 weeks until the infants
became seronegative. 
Diagnosis of CMV infection
Diagnosis of acquired CMV infection was ascertained by
negative urine CMV culture at birth and positive urine CMV
culture thereafter, and by CMV IgM seroconversion. Clean
voided urine specimens were collected via urine bag at birth
and every 3-4 weeks until 12 weeks after the final transfu-
sion. For those who did not receive transfusion in hospital
A, CMV urine cultures were obtained every 5-6 weeks dur-
ing hospitalization and monthly after discharge. To ensure
viral viability and prevent bacterial overgrowth, all urine spec-
imens were stored at 4℃, and packed in wet ice for transport. 
Isolation of CMV
Urine supernatant samples (0.5 mL) were pipetted into
tissue culture tubes containing MRC-5 cell sheets (ATCC
CCL-171) that had been incubated for 3 days in MEM medi-
um (Gibco/BRL, Rockville, MD, U.S.A.) supplemented with
10% newborn calf serum, 100 unit/ml penicillin and 100  g/
mL streptomycin. Each culture tube was then centrifuged
at 1,700 rpm for 40 min at room temperature to allow the
virus to adsorb onto the cell sheet, treated with MEM medium
containing 5% newborn calf serum, and incubated at 35-36℃
for 1 day. IFA with specific antibodies (DAKO, m#0854,
Denmark) was then carried out on the monolayers. CMV
AD169 (ATCC VR-538) and MRC-5 tissue culture tubes
with or without viral inoculation were used as the positive
and negative controls, respectively. 
Statistical analysis 
Statistical analyses were performed using SPSS 10 for Win-
dows (SPSS, Inc., Chicago, IL, U.S.A.); p<0.05 was consid-
ered statistically significant. Means with standard deviations
are given, and Student t-test, Mann-Whitney test, chi-square
and Fisher’s exact tests were used where appropriate. For eval-
uating the relationship between gestational age and level of
serum CMV IgG, linear regression analysis was used. To test
the difference of rate of decline of serum CMV IgG from birth
between transfused and nontransfused groups, summary statis-
tic approach and Student t-test were used. 
RESULTS
Of 112 eligible VLBWI from hospital A, 1 singleton with
congenital CMV infection and 5 VLBWI whose parents
refused to consent were excluded, resulting in recruitment
of 106 (80 transfused and 26 nontransfused) VLBWI from
hospital A. The parents of all 20 VLBWI eligible for the
study from hospital B provided consent. All infants, includ-
ing 9 sets of twins, were followed for the full study period;
none were lost for follow-up. 
The patient characteristics for the transfused VLBWI are
shown in Table 1. The VLBWI who received filtered-irradi-
ated blood products had more transfusions overall, but the
number of donor exposures was similar between the two
groups. The numbers of VLBWI fed frozen breast milk were
similar in both groups. None of study patients received breast
milk after discharge due to lack of its availability except one
patient in filtered-irradiated blood group who was seroneg-Transfusion-related CMV Infection Among VLBWI 7
ative at birth and never acquired CMV despite of 2 months
period of frozen breast milk feedings. A few infants from hos-
pital A received other blood products: 4 received albumin,
4 intravenous IgG, and 9 were treated with fresh frozen plas-
ma (FFP). None of the infants in the nonfiltered-nonirradi-
ated blood group received other products.
The overall incidence of CMV IgG seropositivity in the
enrolled VLBWI at birth was 121/126 (96%). The CMV
IgG titer correlated with gestational age at birth (Fig. 1):
Linear regression analysis: Ln(IgG)= 0.8410 (s.e:0.8433)+
0.0969 (s.e:0.0293)×gestational age (weeks). The percent-
ages of CMV IgG positivity of the filtered-irradiated and
nonfiltered-nonirradiated blood products were 96% and 93%,
respectively. The CMV IgM was positive only in cases of
acquired infection observed after transfusion.
The overall incidence of acquired CMV infection among
transfused VLBWI was 4/100 (4%): 2/80 (2.5%) for filtered-
irradiated blood and 2/20 (10%) for nonfiltered-nonirradi-
ated blood (p>0.05). All positive urine CMV cultures occurred
during hospitalization and CMV infection was only observed
among the transfused group in hospital A: None of the 26
nontransfused VLBWI in hospital A showed positive urine
CMV culture nor CMV IgM at mean age of 157 days. None
Filtered-
irradiated 
group 
(n=80)
Nonfiltered-
nonirradiated
group 
(n=20)
OR
(95% CI)
p
Value
Birth weight (g)* 1091.56  1114.50  (-144.07-98.19) 0.71
(248.09) (227.08)
GA (weeks)* 28.26 (2.21)28.45 (2.26) (-1.23-0.92) 0.74
Male sex 38 (48%) 8 (40%) 1.36 (0.50-3.68) 0.55
1 min AS* 4.43 (2.18) 4.35 (2.25) 0.93
5 min AS* 7.01 (1.73) 6.05 (1.70) 0.02
Cesarean delivery 32 (40%) 5 (25%) 2.04 (0.68-6.18) 0.30
HMD 41 (51%) 11 (55%) 0.86 (0.32-2.30) 0.81
Sepsis 24 (30%) 2 (10%) 3.86 (0.83-17.94) 0.09
IVH 27 (34%) 8 (40%) 0.76 (0.28-2.09) 0.79
PDA 60 (75%) 4 (25%) 12 (3.59-40.12) <0.001
Breast fed infants 53 (66%) 12 (60%) 1.31 (0.48-3.58) 0.79
Number of 7.06 (6.53) 3.90 (3.11) 0.01
transfusions*
Number of donors* 4.50 (4.26) 3.90 (3.11) 0.45
Table 1. Patient characteristics of transfused VLBWI
*Values are mean (SD). Data were evaluated using Mann-Whitney test
for Apgar scores, number of transfusion and donors, and Student t-test
for birth weight and gestational age.
GA, gestational age; AS, Apgar score; HMD, hyaline membrane disease;
IVH, intraventricular hemorrhage; PDA, patent ductus arteriosus.
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Fig. 1. Relationship between CMV IgG titer and gestational age
at birth.
Pati-
ent
Gesta-
tional
age 
(weeks)
Positive 
CMV
IgG at 
birth
Breast
feeding
Blood trans-
fusion*
(All CMV+
blood)
Day when
urine CMV
culture
became
positive
Pneu-
monitis
Hepa-
titis
Neu-
trope-
nia
Throm-
bo-
cytope-
nia
ABR
Chorio-
retinitis
Bayley 
developmental
assessment
Birth
weight
(g)
1 26+2 917 Yes No FI/6/13/0 93 (20)
�
- + - - Normal→ - Not done
Abnormal 
at 3 yrs
2 28 632 Yes No FI/29/24/20 74 (25)
�
+ + - + Normal - MDI 53 PDI 69
(Corrected age 26 mo)
3 33 1,360 Yes No NFNI/2/2/0 65 (40)
�
- - - - Normal - MDI  80 
PDI  90
(Corrected age 22 mo)
4 28 1,330 Yes Yes NFNI/2/2/0 69 (43)
�
- - + + Normal - MDI  106
PDI  105
(Corrected age 20 mo)
Table 2. Clinical characteristics of VLBWI who acquired CMV infection
*Filtered-irradiated (FI) or Nonfilatered-nonirradiated (NFNI)/Number of donors/Number of PRBC transfusions/Number of platelet transfusions, 
� Time
lapse between positive urine CMV culture and last transfusion in parentheses.
Neutropnenia<1,500/L, Platelet counts<150,000/L.
ABR, auditory brainstem response; MDI , mental development index; PDI, psychomotor developmental index.8 A.R. Kim, Y.K. Lee, K.A. Kim, et al.
of the 4 transfused VLBWI who were seronegative at birth
acquired CMV infection, despite multiple transfusions (range:
4-11 times). Of them, 3 received filtered-irradiated blood
products from seropositive donors and 1 received nonfiltered-
nonirradiated blood products from seropositive donors. 
The clinical characteristics and outcomes of the 4 VLBWI
who acquired CMV infection are shown in Table 2. Only
one VLBWI of the nonfiltered-nonirradiated group was fed
frozen breast milk, receiving it for the first 29 days combined
with formula. 3 of 4 VLBWI who acquired CMV had detec-
table serum CMV antibody titers, but low (8, 8, 14 AU/mL)
at the time of their last transfusion. No one received immu-
noglobulin or albumin. 
The rate of decline of passively acquired CMV IgG anti-
body titers in the 100 transfused infants was not affected by
transfusion (p=0.0585) (Fig. 2, 3), but did differ depending
upon the initial titer. As little as 1-2 months was required
to negatively seroconvert the CMV IgG titer in some cases,
but almost all (97.5%) of the infants were CMV antibody-
negative by 10 months (mean: 5.5 months, range: 36-387
days) (Fig. 4). 
DISCUSSION
Prior to the era of leukoreduction and irradiation, the rate
of CMV acquisition among seropositive VLBWI receiving
transfusions of fresh, CMV unscreened, nonirradiated, non-
filtered blood from a donor population in which seroposi-
tivity varied from 34-45.3% was 0-9% (1, 4, 5) compared
with 0-0.8% after transfusion of CMV seronegative blood
to CMV seronegative recipients (6, 7). The removal of the
vast majority of WBCs from RBCs collected from seroposi-
tive donors decreases the transmission of CMV among seroneg-
ative recipients (8, 9); it has been reported that approximately
5-10% of original WBCs remained in the RBC components
filtered with first-generation filters and this number of WBCs
may be sufficient to transmit CMV to the recipients via lym-
phocyte activation. Some even speculate that irradiation and/
or storage of blood from CMV-seronegative donors cannot
prevent the reactivation of preexisting CMV in recipients,
because non-viable irradiated WBCs retain antigenicity and
may trigger the activation of CMV in lymphocytes of infect-
ed recipients.
In our study, the rate of CMV infection was 4% among
seropositive VLBWI from a blood donor population with
95% CMV seropositivity. The rate of acquired CMV infec-
tion was 2/80 (2.5%) in the filtered, irradiated group com-
pared to 2/20 (10%) in the nonfiltered-nonirradiated group
(p>0.05), suggesting that filtering or irradiation of CMV
seropositive blood products did not seem to significantly
reduce transfusion-associated CMV infection among VLBWI
in hyperendemic area. The rate of CMV acquisition among
seronegative VLBWI was 0% despite of multiple nonfiltered-
nonirradiated transfusions with CMV seropositive bloods
which may have been related to limited number of seroneg-
ative VLBWI. The overall observed power in our sample was
only 0.233.
The rate of CMV acquisition among filtered, irradiated
group is substantially lower than that of 9% incidence of
CMV infection found in a similar study using a donor pop-
ulation with 97-100% CMV seropositivity (10). The differ-
ence in the rate of CMV infection when VLBWI were given
filtered-irradiated blood in similar hyperendemic areas may
arise from differences in the use of breast milk feedings (11,
12). Neither of the 2 VLBWI who acquired CMV in the
filtered-irradiated group in our study were fed any breast
milk, while almost all of the subjects in the previous study
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Fig. 2. Changes of serum CMV IgG over time among transfused
VLBWI.
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Fig. 3. Changes of serum CMV IgG over time among nontrans-
fused VLBWI.
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Fig. 4. Changes of serum CMV IgG among all VLBWI.(10) were fed expressed maternal breast milk. We also used
blood that had been stored for longer periods, a practice that
results in lower transmission rates (13, 14). 
It is important to note that in contrast to the serious mor-
bidity related to primary CMV disease reported among sero-
negative recipients of seropositive blood (15-17), there were
no CMV-associated fatalities in our CMV-infected VLBWI
or in those reported by Ohto et al. (10). This may suggests
that maternally-derived CMV antibodies are capable of mod-
ifying the severity of CMV infection (18-20) as reported in
acquired CMV infection transmitted via breast milk in endem-
ic area (21, 22). However, this protective mechanism may
not last long, as passively transferred CMV IgG eventually
decreases. Galea et al. reported that 36 of 38 VLBWI lost
their passive CMV antibodies within 10 months (6). Simi-
larly, we found that 97.5% of our VLBWI seroconverted
within 9-10 months (mean: 5.5 months, range: 36-387 days),
and the rate of CMV antibody loss was not affected by trans-
fusions including FFP (p=0.058). These results strongly sup-
port the use of WBC-reduced cellular blood components (or
equivalent measures) as infants reach seronegative status. This
should reduce transfusion-transmitted CMV infection in the
examined hyperendemic areas as those neonates born with
CMV seronegativity receiving unscreen or CMV seropositive
blood in less endemic area (23, 24). Furthermore, medical
staff in hyperendemic areas should plan to monitor CMV
IgG levels at regular intervals to detect the turning point of
seroconversion.
It has been suggested that the use of  -irradiation will
decreases transfusion-transmitted CMV infection by mount-
ing an immune response via indirect prevention of T-lym-
phocyte proliferation (25, 26) and the use of  -irradiated
blood products in newborn infants has been strongly sug-
gested (27). We found a CMV infection rate of 2/20 (10%)
using relatively fresh nonirradiated-nonfiltered blood in com-
parison to the previously reported 1/19 (5%) (10) using irra-
diated-nonfiltered seropositive blood. Infected 1 of 2 VLBWI
in our nonirradiated-nonfiltered blood group had been fed
with frozen breast milk. Although freezing breast milk is
thought to reduce CMV infectivity (28) and nosocomial trans-
mission of CMV may not occur frequently (29), the extent
to which this infant was exposed to breast milk and other
potential source of nosocomial source is unknown. Based on
our findings, further investigation is warranted to delineate
the effect of irradiation to reduce CMV infection. 
The total volume of transfused blood has been identified
as an important risk factor for the development of significant
transfusion-transmitted CMV disease. Yeager et al. (4) report-
ed that 24% of infants who were born to seronegative mothers
but received more than 50 mL of PRBC from at least one
seropositive donor became infected. Consistent with this,
the volume of PRBC required for VLBWI who acquired
CMV infection in our population of hospital A far exceeded
those who did not acquired CMV infection (230 mL/patient
vs. 68.9 mL/patient). Beneke et al. reported that higher geo-
metric mean titers of CMV IgG of transfused blood may pre-
vent transmission of CMV (30). In contrast, our study showed
that CMV IgG titers of the transfused blood was higher but
not statistically significant in infants who acquired CMV
infection than those who did not (36.1±27.5 AU/mL vs.
31.6±20.1 AU/mL). The mean CMV IgG titers of the recip-
ients sera were similar between these groups (23.6±11.8
AU/mL vs. 21.6±31.4 AU/mL). 
Several limitations of this study include lack of control
for nosocomial, environmental infection (breast milk) and
the small sample size. For a prospective randomized trial,
we would need 177 transfused infants per group assuming a
relative risk of 0.25 (or a relative reduction rate of 75% from
0.10 to 0.025), p<0.05, and power of 0.80. 
In addition, lack of randomization, too few infants of seroneg-
ativity, recruitment of 2 groups from 2 hospitals and lack of
groups receiving irradiated-only and filtered-only blood prod-
ucts may have limited our ability to conclude on what inter-
vention is important. 
In conclusion, the results from this pilot study suggests
that filtering or irradiation of CMV seropositive blood prod-
ucts including PRBC and platelets did not significantly reduce
transfusion-associated CMV infection among VLBWI in
hyperendemic area and even if they acquired the infection,
the impact of its illness is not as serious as those CMV seroneg-
ative recipients. Further validation is warranted in a larger
cohort of infants. 
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